AMGN Logo

Amgen Inc. (AMGN) 

NASDAQ
Market Cap
$149.66B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
535 of 966
Rank in Industry
11 of 12

Largest Insider Buys in Sector

AMGN Stock Price History Chart

AMGN Stock Performance

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Insider Activity of Amgen Inc.

Over the last 12 months, insiders at Amgen Inc. have bought $0 and sold $662,802 worth of Amgen Inc. stock.

On average, over the past 5 years, insiders at Amgen Inc. have bought $0 and sold $5.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 6,020 shares for transaction amount of $1M was made by Hassan Fred (director) on 2015‑08‑19.

List of Insider Buy and Sell Transactions, Amgen Inc.

2024-05-03SaleSVP & CCO
2,117
0.0004%
$313.09$662,802+2.47%
2023-12-04SaleSVP & CCO
2,096
0.0004%
$273.03$572,276+11.78%
2023-11-08SaleEVP, Gen. Counsel & Secy.
10,000
0.0019%
$272.81$2.73M+11.12%
2023-08-10SaleEVP, Global Commercial Ops
9,558
0.0018%
$262.43$2.51M+5.68%
2022-11-09SaleSVP, Business Development
387
<0.0001%
$292.90$113,352-11.93%
2022-11-08SaleSVP & CCO
545
0.0001%
$293.54$159,977-12.76%
2022-08-22Sale
200
<0.0001%
$249.96$49,992-1.11%
2022-08-18Sale
6,600
0.0012%
$249.00$1.64M-2.22%
2022-05-23Sale
1,200
0.0002%
$250.00$300,000-0.65%
2022-05-10SaleEVP, Gen. Counsel & Secy.
27,000
0.0051%
$241.81$6.53M+3.63%
2021-05-12Saledirector
2,000
0.0002%
$161.12$322,230-6.81%
2021-05-11SaleSVP & CCO
5,000
0.0007%
$207.55$1.04M-7.35%
2021-05-07Saledirector
500
<0.0001%
$251.78$125,890-8.09%
2021-04-14Saledirector
2,000
0.0002%
$160.81$321,620-6.30%
2021-03-10Saledirector
2,000
0.0002%
$151.59$303,170+1.39%
2021-02-10Saledirector
2,000
0.0002%
$155.02$310,040-1.80%
2021-02-08Saledirector
500
<0.0001%
$119.00$59,498-1.43%
2021-02-04SaleEVP, Gen. Counsel & Secy.
22,220
0.0038%
$236.51$5.26M-1.28%
2021-01-13Saledirector
2,000
0.0002%
$118.00$235,990-0.60%
2020-11-09Saledirector
500
<0.0001%
$121.20$60,600+1.39%

Insider Historical Profitability

3.98%
Grygiel Nancy A.SVP & CCO
9883
0.0018%
$278.4204
JOHNSON FRANKLIN P JRdirector
1636961
0.3045%
$278.42015
Bradway Robert AChairman, CEO and President
383102
0.0713%
$278.4212+39.22%
FRITZKY EDWARD Vdirector
231000
0.043%
$278.4208
PERLMUTTER ROGER MEVP, Research & Development
186031
0.0346%
$278.4206
OMENN GILBERT Sdirector
176783
0.0329%
$278.4207
LAZARUS STEVENdirector
149343
0.0278%
$278.4205
FENTON DENNIS MExecutive V.P., Operations
117518
0.0219%
$278.42020
MORROW GEORGE JExe VP, Global Commercial Ops
93719
0.0174%
$278.4214<0.0001%
ODRE STEVEN MSr. VP, Gen. Counsel & Secy.
76705
0.0143%
$278.4202
SCOTT DAVID JSVP, Gen. Counsel & Secy.
65558
0.0122%
$278.4204
Harper Sean EEVP, Research & Development
56082
0.0104%
$278.42015
Balachandran MadhavanEVP, Operations
55996
0.0104%
$278.4204
MCNAMEE BRIAN MEVP
54643
0.0102%
$278.42019
Meline David WEVP & CFO
49378
0.0092%
$278.4201
CHOATE JERRY Ddirector
48575
0.009%
$278.4212<0.0001%
BONANNI FABRIZIOEVP, Operations
48491
0.009%
$278.42013
Gordon MurdoEVP, Global Commercial Ops
44308
0.0082%
$278.4201
Flanagan Thomas JamesSr VP & CIO
41826
0.0078%
$278.4204
Michael A KellyActing CFO
41041
0.0076%
$278.4206
Piacquad DavidSVP, Business Development
39700
0.0074%
$278.4201
BEIER DAVID WSVP, Global Govt Affairs
35612
0.0066%
$278.4207
BALTIMORE DAVIDdirector
31159
0.0058%
$278.4208
BIONDI FRANKdirector
29780
0.0055%
$278.4204
Graham Jonathan PEVP, Gen. Counsel & Secy.
28078
0.0052%
$278.4204
REASON J PAULdirector
23591
0.0044%
$278.4202
MILETICH JOSEPH PSr VP Rsch & Preclinical Dev
22500
0.0042%
$278.4201
Patton Cynthia MSVP & CCO
22097
0.0041%
$278.4206
Tross Stuart ASVP, Human Resources
21923
0.0041%
$278.4202
ECKERT ROBERT
21184
0.0039%
$278.4201
Dittrich Thomas J.W.VP, Finance & CAO
18589
0.0035%
$278.4205
SCHAEFFER LEONARD Ddirector
16329
0.003%
$278.4202
SUGAR RONALD Ddirector
15927
0.003%
$278.42020
GLUCK FREDERICK Wdirector
15748
0.0029%
$278.4213<0.0001%
de Carbonnel Francoisdirector
15528
0.0029%
$278.4224+16.13%
PELHAM JUDITH Cdirector
11890
0.0022%
$278.4209
COFFMAN VANCE Ddirector
10668
0.002%
$278.4210<0.0001%
NANULA RICHARD DExe VP & CFO
10000
0.0019%
$278.4206
RICHO ANNASVP & CCO
10256
0.0019%
$278.42012
Jacks Tylerdirector
8979
0.0017%
$278.4201
Such Annette LouiseVP, Finance and CAO
7183
0.0013%
$278.4201
Khosla RachnaSVP, Business Development
6630
0.0012%
$278.4201
SHARER KEVIN Wdirector
5494
0.001%
$278.42015
HENDERSON REBECCA Mdirector
5549
0.001%
$278.4202
Williams R Sanders
5301
0.001%
$278.42010
Hassan Freddirector
3582
0.0007%
$278.4210<0.0001%
HERRINGER FRANK Cdirector
2000
0.0004%
$278.4220+3.73%
DAYEM HASSANSr. V.P. & Chief Info. Officer
1349
0.0003%
$278.4202
SCHEHR BARRY DVP Financial Ops & CAO
0
0%
$278.4203

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$14.81B9.7152.09M+6.21%+$865.94M0.27
BlackRock$13.64B8.9447.97M+0.33%+$45.12M0.3
State Street$8.28B5.4329.13M-1.13%-$94.3M0.34
PRIMECAP Management Co$4.15B2.7214.6M+0.07%+$2.98M3.05
Morgan Stanley$3.97B2.6113.97M-3.2%-$131.38M0.29
Geode Capital Management$3.3B2.1711.64M-5.64%-$197.61M0.28
Charles Schwab$3.08B2.0210.83M+4.23%+$124.88M0.67
Wells Fargo$2.13B1.47.5M+0.19%+$3.95M0.57
Capital International Investors$1.99B1.317.01M+547.82%+$1.68B0.4
Northern Trust$1.71B1.126.02M-6.18%-$112.7M0.28
Capital Research Global Investors$1.61B1.065.67M-15.45%-$294.52M0.37
Royal Bank of Canada$1.55B1.025.46M-6.37%-$105.61M0.37
BNY Mellon$1.52B15.36M-2.43%-$37.91M0.29
Legal & General$1.41B0.934.97M-0.99%-$14.16M0.33
Barclays$1.23B0.814.34M+48.91%+$405.56M0.56
Goldman Sachs$1.22B0.84.3M+11.73%+$128.46M0.23
Aristotle$1.15B0.754.04M-2.67%-$31.49M2.2
Fidelity Investments$1.14B0.754.02M-15.87%-$215.38M0.08
UBS$1.07B0.73.75M+11.52%+$110.06M0.32
JPMorgan Chase$1.02B0.673.57M-9.91%-$111.69M0.09
Nuveen$990.96M0.653.49M-2.33%-$23.59M0.28
Ubs Asset Management Americas Inc$957.17M0.633.37M-7.03%-$72.39M0.34
Amundi$885.05M0.633.37M+11.21%+$89.21M0.37
Bank of America$946.15M0.623.33M-21.9%-$265.28M0.09
Deutsche Bank$926.78M0.613.26M+17.34%+$136.92M0.42
T. Rowe Price$892.05M0.593.14M-52.21%-$974.43M0.11
Invesco$880.4M0.583.1M-11.14%-$110.41M0.18
CalPERS$782.54M0.512.75M+1.33%+$10.3M0.55
State Farm$772.12M0.512.72M0%+$00.7
Dimensional Fund Advisors$722M0.472.54M+2.53%+$17.81M0.19
Janus Henderson$676.98M0.442.38M+137.13%+$391.5M0.34
Boston Partners$635.18M0.422.24M+27.4%+$136.62M0.75
Ameriprise Financial$561.15M0.371.97M-8.87%-$54.65M0.16
AllianceBernstein$555.34M0.361.95M-5.17%-$30.29M0.2
Montrusco Bolton Investments Inc$501.76M0.341.81M+60.65%+$189.43M5.37
Nordea Investment Management Ab$515.23M0.341.8M-0.02%-$86,182.320.61
Franklin Templeton Investments$480.59M0.321.69M+4.01%+$18.51M0.14
HSBC$478.06M0.311.68M+14.55%+$60.72M0.34
Sumitomo Mitsui Trust Holdings$471.98M0.311.66M+0.19%+$889,068.640.32
Swiss National Bank$455.69M0.31.6M-4.18%-$19.9M0.3
Beutel, Goodman & Company Ltd.$452.43M0.31.59M+1.38%+$6.14M2.33
Federated Hermes$418.5M0.271.47M-15.34%-$75.85M0.97
Stifel$407.51M0.271.43M+5.52%+$21.31M0.47
LSV Asset Management$386.71M0.251.36M-25.68%-$133.66M0.8
Allianz Asset Management Gmbh$383.78M0.251.35M+5.76%+$20.92M0.65
Envestnet Asset Management Inc$370.09M0.241.3M+7.37%+$25.4M0.14
Bank of Montreal$350.08M0.231.22M-32.16%-$166M0.11
Sarasin & Partners LLP$324.52M0.211.14M-0.55%-$1.79M3.2
Credit Suisse$311.64M0.21.1M-5.08%-$16.69M0.29
PNC Financial Services$307.43M0.21.08M-1.86%-$5.83M0.22
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.